News & Events about Aeglea Biotherapeutics Inc.
StockNews.com began coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE Get Rating) in a research note released on Monday morning. The firm issued a hold rating on the biotechnology companys stock. AGLE has been the topic of several other research reports. Piper Sandler increased their target ...
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency PR Newswire AUSTIN, Texas, Jan. 6, 2023 Streamlining of organization to focus on near-term deliverables...
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE Get Rating) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 611,000 shares, an increase of 17.8% from the October 15th total of 518,700 shares. Based on an average daily trading ...
Ticker Report
3 months ago
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE Get Rating) was the target of a large decline in short interest in the month of October. As of October 15th, there was short interest totalling 518,700 shares, a decline of 24.1% from the September 30th total of 683,100 shares. Based on an average ...
Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring PR Newswire AUSTIN, Texas, Aug. 24, 2022 PrioritizingResources and Focus on AGLE-177 and the Completion of the Ongoing Phase 1/2...